Gyre Therapeutics (GYRE) to Release Earnings on Thursday

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $28.40 million for the quarter.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03). The business had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Gyre Therapeutics Stock Performance

GYRE traded down $0.35 during mid-day trading on Tuesday, reaching $8.47. The stock had a trading volume of 67,848 shares, compared to its average volume of 93,144. The stock has a market capitalization of $793.53 million, a P/E ratio of 168.80 and a beta of 1.90. Gyre Therapeutics has a 52 week low of $6.11 and a 52 week high of $19.00. The firm's fifty day simple moving average is $9.23 and its two-hundred day simple moving average is $11.08.

Hedge Funds Weigh In On Gyre Therapeutics

A hedge fund recently raised its stake in Gyre Therapeutics stock. Bank of America Corp DE increased its holdings in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,937 shares of the company's stock after acquiring an additional 1,996 shares during the quarter. Bank of America Corp DE's holdings in Gyre Therapeutics were worth $84,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 23.99% of the company's stock.

Analysts Set New Price Targets

Separately, Noble Financial began coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating on the stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.